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A preclinical screen to evaluate pharmacotherapies for the
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Agitation associated with dementia is frequently reported
clinically but has received little attention in preclinical
models of dementia. The current study used a 7PA2 CM
intracerebroventricular injection model of Alzheimer’s
disease (AD) to assess acute memory impairment, and a
bilateral intrahippocampal (IH) injection model of AD
(aggregated Aβ1–42 injections) and a bilateral IH injection
model of dementia with Lewy bodies (aggregated NAC61–95
injections) to assess chronic memory impairment in the rat.
An alternating-lever cyclic-ratio schedule of operant
responding was used for data collection, where incorrect
lever perseverations measured executive function
(memory) and running response rates (RRR) measured
behavioral output (agitation). The results indicate that
bilateral IH injections of Aβ1–42 and bilateral IH injections of
NAC61–95 decreased memory function and increased RRRs,
whereas intracerebroventricular injections of 7PA2 CM
decreased memory function but did not increase RRRs.
These findings show that using the aggregated peptide IH
injection models of dementia to induce chronic
neurotoxicity, memory decline was accompanied by
elevated behavioral output. This demonstrates that IH
peptide injection models of dementia provide a preclinical
screen for pharmacological interventions used in the
treatment of increased behavioral output (agitation), which
also establish detrimental side effects on
memory. Behavioural Pharmacology 00:000–000 Copyright
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Introduction
A significant number of patients suffering from dementia
exhibit behaviors indicative of agitation (Ryu et al., 2005;
Savva et al., 2009), such as restlessness and disturbed
sleep (Cipriani et al., 2014), and it has been estimated that
∼ 90% of dementia sufferers develop behavioral pro-
blems that supersede the seminal symptom of memory
dysfunction (Tariot and Blazina, 1993). Agitation is found
in Alzheimer’s disease (AD), dementia with Lewy bodies
(DLB), frontotemporal dementia, and other syndromes
resulting in dementia (Ballard and Corbett, 2010;
Manoochehri and Huey, 2012; Burns and Josephs, 2013).
Agitation has been defined as inappropriate verbal, vocal,
or motor activity that is unexplained by apparent needs or
confusion (Cohen-Mansfield and Billig, 1986). Although
agitation might include aggressive behaviors, it can occur
without aggression (Cummings et al., 2015), and when it
is severe it requires pharmacological treatment
(Herrmann and Lanctot, 2007). The treatment of agita-
tion has been identified as an unmet need in relation to
adequate care provided for those suffering from cognitive
impairments (Herrmann and Lanctot, 2007; Gitlin et al.,
2012). When the agitation is severe the symptoms
include disinhibition, irritability, aggression, and aberrant
motor activity, which affect the patient’s quality of life
and cause increased stress for the family and caregivers
(Kales et al., 2014; Antonsdottir et al., 2015; Cummings
et al., 2015; Panza et al., 2015).
This aspect of dementia has been largely overlooked in
the employment of laboratory-based animal models of
dementia, where the focus has been directed toward
establishing neuropathological and behavioral features
reflecting a decline in memory abilities. Agitation related
to dementia is frequently observed clinically (Lyketsos
et al., 2000; Ballard et al., 2001; Cohen-Mansfield, 2013),
and various pharmacological interventions have been
used to treat this. These treatments include the use of
anxiolytic, antidepressant, antipsychotic, and antic-
onvulsant drugs (Salzman et al., 2008; Kales et al., 2014;
Antonsdottir et al., 2015; Cummings et al., 2015; Panza
et al., 2015; Soto et al., 2015). The most contentious
approach relates to the use of antipsychotic drugs (Jeste
et al., 2008), which have been reported to be of only
modest value (Schneider et al., 2006a, 2006b; Ballard
et al., 2009), and to produce adverse effects (Gitlin et al.,
2012). Overall, the currently available pharmacological
treatments for agitation in dementia are of little value,
and the adverse effects of antipsychotic drugs are of
considerable concern (Ballard, 2006; Schneider et al.,
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2006a, 2006b; Sacchetti et al., 2012; Ma et al., 2014).
Basically, there are no officially approved pharma-
cotherapies for agitation in dementia, and few if any safe
and effective pharmacotherapies (Salzman et al., 2008;
Kales et al., 2014; Antonsdottir et al., 2015; Cummings
et al., 2015; Panza et al., 2015; Soto et al., 2015). Further,
nonpharmaceutical approaches have been shown to be of
very limited value (Kales et al., 2014; Ballard et al., 2016;
Steinberg, 2016). Of the pharmacological treatments used
for the management of agitation in dementia, benzodia-
zepines (anxiolytics) have weak effects (Salzman et al.,
2008; Wilson et al., 2012; Kales et al., 2014; Defrancesco
et al., 2015; Ngo and Holroyd-Leduc, 2015) and have
been found to accelerate cognitive deterioration
(Defrancesco et al., 2015), the antidepressants citalopram
(Pollock et al., 2002) and sertraline (Lyketsos et al., 2003)
have been suggested to have some effects (Sink et al.,
2005), but the trial using citalopram had a high dropout
rate due to lack of efficacy, and sertraline had no benefit
with respect to neuropsychiatric symptoms.
Antipsychotics are of modest value (Ballard et al., 2009;
Gitlin et al., 2012) but induce adverse cerebrovascular
events, especially during the first weeks of treatment
(Sacchetti et al., 2012; Wu et al., 2013), and increase
mortality (Ballard, 2006; Schneider et al., 2006a, 2006b;
Sacchetti et al., 2012; Ma et al., 2014), and anticonvulsants
raise concerns with respect to tolerability (Gallagher and
Herrmann, 2014). Consequently, a preclinical model of
dementia that measures adverse effects on memory (the
seminal symptom of dementia), and also models the
agitation commonly observed clinically, would be useful
for screening pharmacotherapies for the treatment of
agitation in dementia.
The most widely known form of dementia is AD, which
is associated with the accumulation of amyloid-β (Aβ)
plaques in the brain (e.g. Glenner and Wong, 1984). It
accounts for up to 80% of all cases of dementia (Hebert
et al., 2013) and is comprehensively documented. DLB is
the second most common form of dementia: it presents in
∼ 40% of Parkinson’s disease cases (Poewe, 2005), and
the severity of DLB correlates significantly with the
density of Lewy body deposition in the brain (Hurtig
et al., 2000). Whereas Aβ1–42 (the most toxic form of Aβ)
and Aβ1–40 are major components of the aggregated pla-
ques found in AD, aggregated α-synuclein is the major
component of Lewy bodies (Spillantini et al., 1998), and
the nonamyloid component (NAC) region of α-synuclein,
residues 61–95 (NAC61–95), is essential for the aggrega-
tion and toxicity of α-synuclein (El-Agnaf et al., 1998).
NAC61–95 was first isolated from the amyloid plaques
associated with AD (Ueda et al., 1993), and this region of
α-synuclein has been linked with an increased propensity
of α-synuclein to form fibrils (Jethva et al., 2011). The
fibrillogenic capacity of NAC61–95 is well documented,
and the extracellular aggregation of NAC and
intracellular accumulation of α-synuclein are considered
to be contributory factors in the pathogenesis of DLB
and AD.
Consequently, to determine whether an animal model of
dementia can reflect the increased behavioral output
(agitation) commonly reported in clinical observations of
patients suffering from dementia, the current study used
a bilateral intrahippocampal (IH) injection model of the
effect of aggregated Aβ1–42 in AD, and a bilateral IH
injection model of the effect of aggregated NAC61–95 in
DLB to produce chronic neurotoxic peptide deposits in
the brain. Although recent theories relating to the onset
of dementia, and in particular AD, suggest that the pre-
cipitating event is the disruption of synaptic transmission
due to the formation of the oligomeric configuration of
the neurotoxic peptide (e.g. Haas and Selkoe, 2007;
Walsh and Selkoe, 2007; Klyubin et al., 2008; Shankar
et al., 2008; Ondrejcak et al., 2010; Pharm et al., 2010),
very few patients presenting clinically with symptoms of
memory decline are likely to be at such an early stage of
disease progression. However, the intracerebroven-
tricular (ICV) 7PA2 CM injection model of AD (e.g.
Cleary et al., 2005) was used to determine the effects of
acute synaptotoxicity on increased behavioral output,
even though clinical management of typical dementia
cases generally involves the use of drugs for the treat-
ment of agitation following diagnosis at the stage of
pathogenesis when aggregated neurotoxic peptides are
chronically established in the brain.
The operant technique employed was the alternating-
lever cyclic-ratio (ALCR) schedule (Weldon et al., 1996).
This experimental evaluation of behavior has been used
to assess the effects of bilateral IH injections of aggre-
gated Aβ1–42 (O’Hare et al., 1999; Richardson et al., 2002),
bilateral IH injection of aggregated NAC61–95 (Kim et al.,
2009; O’Hare et al., 2010a, 2010b), and ICV injections of
7PA2 CM in the rat (e.g. Cleary et al., 2005; Poling et al.,
2008). The aggregated peptide injections were delivered
into the hippocampus as this is an area of the brain
directly implicated in learning and memory (Jerrard,
1993), and the ALCR schedule was used as this is
recognized as a sensitive, accurate, and parsimonious
determinant of memory function in the rat (Cleary et al.,
2005; Poling et al., 2008). Also, the ALCR provides data
indicating experimental effects on running response rates
(RRRs). RRRs illustrate increases or decreases in beha-
vioral output, and increased RRRs may be analogous to
the increased behavioral output seen as agitation in
human dementia.
The RRR is the rate of lever press responding at any
given operant ratio response value, minus the post-
reinforcement pause duration (Ferster and Skinner,
1957). The post-reinforcement pause duration is the time
spent after receiving a reinforcer (generally a food pellet
for experimental animals) before beginning the next
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lever press engagement for production of the next rein-
forcer. Consequently, RRRs provide a measure of actual
lever-pressing activity per unit of lever-pressing time.
This observation is generally incorporated in operant
experiments to ensure that malaise or peripheral motor
impedance resulting from an experimental manipulation
is not misinterpreted as an adverse central nervous sys-
tem effect on memory-related behavioral measurements.
That is, an observed decline in cognitive (memory)
ability that correlates with a reduction in RRRs might
simply be a reflection of the physical inability of an ani-
mal, due to malaise or illness, to complete a required task
(seen as a decrease in activity, and misinterpreted as an
effect on memory). In the current study, data on RRRs
were collected to determine whether the induction of
neurotoxicity might affect RRRs in a manner that indi-
cated the development of agitation. These data were
used to determine whether an increase in RRRs, possibly
inferring the agitation commonly seen in the syndrome
reported for human patients suffering from dementia,
was an inherent feature of experimentally induced
memory dysfunction due to acute synaptotoxicity (ICV
7PA2 CM injections), or chronic neurotoxicity due to the
presence of neurotoxic peptide aggregates in the hippo-
campal region of the brain.
Methods
Subjects
Forty-eight male Sprague-Dawley rats (Harlan, UK),
weighing 229–250 g at the beginning of the experiment,
were maintained at 90% of their free-feeding body
weights, and housed individually with water freely
available in the home cage. The temperature in the
vivarium was maintained at 23°C under a 12-h-light/12-h-
dark cycle (lights on at 08:00 h). The relative humidity of
the vivarium was maintained at 50–65%, and light
intensity was controlled at a maximum of 9 lux in the
home cage. This work was approved by the relevant
institutional ethics committees and conducted under
Home Office License (UK).
Apparatus
Ten two-lever rat test chambers (Med Associates Inc., St
Albans, New Jersey, USA) enclosed in sound-attenuating
compartments were employed. Food reinforcers were
45 mg sucrose food pellets (BioServ, Frenchtown, New
Jersey, USA) that were delivered into a tray situated
midway between the two operant levers. A Siemens
computer programmed in MED-PC (Med
Associates Inc.) controlled the experiment and collected
data. The operant test chambers had internal dimensions
of 30.5 cm length× 24.1 cm width× 21 cm height. The
pellet receptacle was 2.9 cm wide× 2.5 cm high× 1.9 cm
deep, and was situated in the center of the 24.1 cm
chamber wall. The retractable operant response levers
were 4.8 cm wide× 1.9 cm deep and were positioned
2.1 cm above the floor of the chamber on each side of the
pellet receptacle. The house light was situated in the
center of the chamber ceiling, and when illuminated had
an output of 3W.
Behavioral training
The training procedure adopted has previously been
reported extensively (e.g. Weldon et al., 1996; Richardson
et al., 2002; Cleary et al., 2005). Briefly, behavioral ses-
sions were conducted 7 days/week, during which the rats
were trained to press both levers for food reinforcement,
each operant training session lasting for a maximum of
50 min. Approximately AQ320–30 sessions after the initial
lever press training, the ALCR schedule was introduced.
Using this schedule, rats alternate to the other lever after
pressing the currently correct lever a sufficient number of
times to obtain a food reinforcer. The number of lever
presses required for each reinforcer changes, increasing
from two responses per food pellet to 56 responses per
food pellet, and then decreasing back to two responses
per food pellet, repeated over six cycles. One complete
cycle requires alternating-lever responses of 2, 6, 12, 20,
30, 42, 56, 56, 42, 30, 20, 12, 6, and 2. The requirement to
alternate levers generates data on incorrect lever perse-
verations, which indicate disruption of well-learned
behaviors, or reference memory, including general
aspects of executive function, reasoning, and goal-
oriented manipulation of previously acquired informa-
tion (Cleary et al., 2005; Poling et al., 2008). The ALCR
schedule also measures RRRs; these are response rates at
each schedule value, minus the post-reinforcement pause
duration. Consequently, RRRs provide a measure of
actual lever-pressing activity per unit of lever-pressing
time, thereby indicating the general level of activity.
7PA2 conditioned medium
7PA2 cells are stably transfected Chinese hamster ovary
cells that incorporate the cDNA for amyloid precursor
protein (APP751); this is specific for the familial AD
mutation Val171Phe (Podlisny et al., 1998; Shankar et al.,
2011). These cells secrete Aβ1–40 and Aβ1–42 (Shankar
et al., 2011), and were grown to just below confluence in
Dulbecco’s Modified Eagle’s medium containing 10%
fetal bovine serum and 200 µg/ml G418. They were
briefly washed in DPS and incubated at 37°C with 5%
CO2 for 18 h with a sufficient volume of Dulbecco’s
Modified Eagle’s medium to cover the cells. After incu-
bation the medium was centrifuged at 3000g for 15 min
and snap-frozen and stored at − 20°C until thawing for
ICV injections. Using enzyme-linked immunosorbent
assay, the concentration of total Aβ in the 7PA2 CM was
in the range of 2–5 nmol/l.
Aggregation of Aβ1–42 and NAC61–95
Aggregated Aβ1–42 and aggregated NAC61–95 were pre-
pared from solutions of 10− 4 mol/l soluble Aβ1–42 or
soluble NAC61–95 peptides AQ4(Sigma, UK) in 0.01 mol/l
filtered PBS (pH 7.4) (Weldon et al., 1998). The Aβ1–42
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and NAC61–95 solutions were agitated (Teflon-coated
stirbar at 200 rpm) at room temperature for 36 h.
Following agitation, both solutions (Aβ1–42 and
NAC61–95) were turbid. The Aβ1–42 and NAC61–95 pep-
tides were then sedimented by centrifugation
(10 min× 15 000g) to 80% sedimentation of each peptide.
These sediments of aggregated Aβ1–42 and aggregated
NAC61–95 were then dissolved with PBS, aliquoted, and
stored at − 20°C before thawing for bilateral IH
injections.
Surgical procedure
When all rats were able to complete the ALCR schedule
in 50 min without demonstrating changes in operant
response trends, they were anesthetized with fentanyl
citrate (0.4 ml/kg) and placed in a stereotaxic frame
(Kopf, USA). For ICV injections (7PA2 CM administra-
tion), 16 rats were fitted with a permanently indwelling
cannula (23 G) aimed at the lateral cerebral ventricle.
Half of the rats in each randomly assigned group
(experimental and control) received left lateral ventricle
cannula implants and the other half received right lateral
ventricle cannula implants. With the incisor bar set
3.5 mm below the interaural line, the stereotaxic coordi-
nates for cannula implantation were 1.0 mm posterior and
± 1.5 mm lateral to Bregma, and 3.0 mm below the pial
surface (Paxinos and Watson, 1998). Cannula placement
and patency were verified by vigorous drinking (>5 ml/
20 min) following ICV injection of 0.5 µg/ml of angio-
tensin II (Johnson and Epstein, 1974). Following a 7-day
recovery period from surgery, the experimental group
was injected ICV with 10 µl of 7PA2 CM and the control
group was injected ICV with 10 µl of CHO CM (wild-
type control), and initial behavioral testing was con-
ducted 2 h following ICV injections. This temporal
sequence for behavioral testing following 7PA2 CM ICV
injections has been previously explained, and the effect
on memory dissipates within 24 h after injection (Cleary
et al., 2005).
For IH injections (aggregated Aβ1–42 and aggregated
NAC61–95) the remaining 32 rats were fitted with per-
manently indwelling bilateral cannulae aimed at the CA3
region of the dorsal hippocampus of the brain, with the
incisor bar set 3.5 mm below the interaural line; the ste-
reotaxic coordinates were 3.3 mm posterior and ± 2.6 mm
lateral to Bregma and 3.7 mm below the pial surface
(Paxinos and Watson, 1998). Following a 7-day recovery
period from surgery the rats were randomly assigned to
groups. Sixteen rats were assigned to the aggregated
Aβ1–42 experimental group, of which eight received
bilateral IH injection of aggregated Aβ1–42 and eight
received bilateral IH injection of sterile water, and 16 rats
were assigned to the aggregated NAC61–95 group, of
which eight received bilateral IH injection of aggregated
NAC61–95 and eight received bilateral IH injection of
sterile water. These experimental subjects were injected
bilaterally IH with 5 µl (per side) of aggregated Aβ1–42
(n= 8) and the corresponding control group was injected
bilaterally IH with 5 µl (per side) of sterile water (n= 8);
the remaining IH group was injected bilaterally IH with
5 µl (per side) of aggregated NAC61–95 (n= 8) and the
corresponding control group was injected bilaterally IH
with 5 µl (per side) of sterile water (n= 8). Using a 26 G
needle connected to a Hamilton microsyringe, injectates
were deposited slowly over a 15 min period, and the
injector remained in place for a further 2 min. Sterile
water was used as the control injectate because this was
the case in other behavioral studies of this nature, and
adhering to this procedure ensured that the data were
comparable to those of previously published studies. Ten
days after the bilateral IH injections, the collection of
behavioral data resumed. Data were collected daily from
all six cycles of the ALCR schedule for each subject in
each group. Following the collection of behavioral data
from the IH-injected groups (aggregated Aβ1–42 and
aggregated NAC61–95 and their IH-injected sterile water
control counterparts), these rats were bilaterally injected
IH with 1 µl of Evans blue (per side). All of the IH-
injected rats were then deeply anesthetized and perfused
through the ascending aorta with 4% paraformaldehyde.
Using a cryostat, the brains were then sectioned through
the plane of the IH microinjection sites and viewed using
a light microscope for confirmation of the position of each
IH injection.
Statistical analyses
The ICV 7PA2 CM versus CHO CM data on incorrect
lever perseverations were analyzed by means of the t-test
everyday (Fig. 1), and the ICV 7PA2 CM RRR data were
analyzed by repeated-measures analysis of variance
(Fig. 2). The aggregated Aβ1–42 versus sterile water data
and the aggregated NAC61–95 versus sterile water data on
incorrect lever perseverations were analyzed by t-test
(Fig. 3). The RRR data (Aβ1–42 and NAC61–95) were
analyzed by daily t-tests in the first instance for deviation
from the control condition and then by repeated-
measures analysis of variance within and between
groups (Figs 4 and 5). The two types of data were ana-
lyzed differently because the analyses of incorrect lever
perseverations tested a-priori predictions about effects at
particular timepoints: AQ5ICV 7PA2 injection effects on
memory have previously been shown to last for less than
24 h, and IH-aggregated peptide injection effects on
memory have previously been shown to take ∼ 30 days to
develop.
Results
ICV injections of 7PA2 CM produced an acute increase
in incorrect lever perseverations (Fig. 1), indicating a
decline in cognitive ability (t14= 5.33, P< 0.001). This
acute effect of 7PA2 CM-induced synaptotoxicity on
behavior, lasting for less than 1 day, has been previously
reported (e.g. Cleary et al., 2005). But ICV 7PA2 CM
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injection had no acute or chronic (up to 50 days after
injection) effect on RRRs within the groups (7PA2 CM:
F50,350= 1.21, NS; CHO CM: F50,350= 1.11, NS) or
between the groups (F1,14= 0.01, NS) (Fig. 2).
Bilateral IH injection of aggregated Aβ1–42, and bilateral
IH injection of aggregated NAC61–95 produced a chronic
increase in incorrect lever perseverations, indicating a
decline in cognitive ability (Aβ1–42 vs. sterile water;
t14=− 24.62, P< 0.001: NAC61–95 vs. sterile water;
t14=− 18.89, P< 0.001) (Fig. 3) from approximately day
30 onward. This finding is consistent with the effects of
IH-aggregated peptide injections on operant behavior in
the rat since its first investigation (Cleary et al., 1995) and
has previously been reported for IH injections of aggre-
gated Aβ1–42 (e.g. O’Hare et al., 1999) and for aggregated
NAC61–95 (e.g. Kim et al., 2009) (Aβ1–42 vs. sterile water
day 1–29; t=− 1.30, P> 0.05: NAC61–95 vs. sterile water
day 1–29; t=− 1.22, P> 0.05). There were no significant
differences in RRRs during approximately the first
Fig. 1
0
20
40
60
80
100
120
140
160
180
200
0 1 2 3 4 5
In
co
rr
ec
t L
ev
er
 P
er
se
ve
ra
tio
n 
(1
00
%
 B
as
el
in
e)
Consecutive Days Post Injection 
CHO CM
7PA2 CM
*
Effect of intracerebroventricular 7PA2 CM injection on incorrect lever
perseverations. Data are represented as mean±SEM (*P<0.001).
Fig. 2
0.0
40.0
80.0
120.0
160.0
200.0
240.0
280.0
320.0
CHO CM
7PA2 CM 
Consecutive Days Post Injection
R
un
ni
ng
 R
es
po
ns
e 
R
at
e 
(R
es
p/
m
in
)
0 10 20 30 40 50
Effect of intracerebroventricular 7PA2 CM injection on running
response rates up to 50 days after injection. Data are represented as
mean ±SEM (repeated-measures analysis of variance within and
between groups P’s>0.05).
Fig. 3
0
100
200
300
400
500
600
700
Sterile Water Aβ1-42
N
um
be
r o
f I
nc
or
re
ct
 L
ev
er
 
P
er
se
ve
ra
tio
ns
 
(A
ve
ra
ge
 d
ay
 3
0-
90
) 
N
um
be
r o
f I
nc
or
re
ct
 L
ev
er
 
P
er
se
ve
ra
tio
ns
 
(A
ve
ra
ge
 d
ay
 3
0-
90
) *
0
100
200
300
400
500
600
700
Sterile Water NAC61-95
*
Effect of bilateral intrahippocampal injections of aggregated Aβ1–42 and aggregated NAC61–95 in the CA3 area of the dorsal hippocampus on
incorrect lever perseverations. Data are represented as mean±SEM (*P<0.001). Aβ, amyloid-β; NAC, nonamyloid component.
Fig. 4
0
40
80
120
160
200
240
280
320
360
400
10 20 30 40 50 60 70 80 90
R
un
ni
ng
 R
es
po
ns
e 
R
at
e 
(r
es
p/
m
in
)
Sterile Water group
Consecutive Days Post Injection
Aβ group
∗
Effect of bilateral intrahippocampal injections of aggregated Aβ1–42 in
the CA3 area of the dorsal hippocampus on running response rates.
Data are represented as mean±SEM (*P<0.001; repeated-measures
analysis of variance within and between groups P’s<0.001). Aβ,
amyloid-β.
AAQ1 screen for treatment of agitation in dementia O’Hare et al. 5
Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
35 days after bilateral IH injection of aggregated Aβ1–42
(Fig. 4); however, RRRs increased significantly in the
aggregated Aβ1–42 group from this point until the end of
the study (P’s< 0.001). Repeated-measures analyses
indicated a significant effect within the groups by days
(Aβ1–42; F80,560= 8.93, P< 0.001: sterile water;
F80,560= 4.26, P< 0.001) and between the groups
(F1,14= 9.19, P< 0.001). There were no significant dif-
ferences in RRRs during approximately the first 35 days
after bilateral IH-aggregated NAC61–95 injection (Fig. 5);
however, RRRs increased significantly in the NAC61–95
group from this point until the end of the study
(P’s< 0.01). Repeated-measures analyses indicated a
significant effect within the groups by days (NAC61–95;
F80,560= 7.76, P< 0.001: sterile water; F80,560= 3.82,
P< 0.001) and between the groups (F1,14= 5.51,
P< 0.05).
Discussion
The current study employed animal models of the two
most prevalent forms of dementia, AD and DLB (Poewe,
2005; Hebert et al., 2013). To establish whether acute
synaptotoxicity was linked to increased behavioral out-
put, the 7PA2 CM ICV injection model of AD was
employed, and to determine whether chronic neuro-
toxicity was linked to increased behavioral output the
bilateral IH injection model of AD (aggregated Aβ1–42)
and the bilateral IH injection model of DLB (aggregated
NAC61–95) were employed. The chronic IH-aggregated
peptide injection models were more likely to approx-
imate the stage of clinical dementia encountered by
physicians at the point of diagnosis of dementia, and at
the later stages of pathogeneses where agitation might be
encountered.
The current study found that ICV injection of 7PA2 CM
produced an acute memory deficit, with full recovery at
24 h after injection, as measured by incorrect lever per-
severations (Fig. 1), but had no effect on RRRs, even at
an extended latency (Fig. 2). This effect of 7PA2 CM on
memory has been reported extensively (e.g. O’Hare et al.,
2016) but not the effect on RRRs. Bilateral IH injection
of aggregated Aβ1–42 and bilateral IH injection of aggre-
gated NAC61–95 produced a significant increase in
incorrect lever perseverations (Fig. 3), and these findings
are also in agreement with previous investigations [Aβ1–42
(e.g. O’Hare et al., 1999) and NAC61–95 (e.g. O’Hare et al.,
2010b)]. Incorrect lever perseverations provide a measure
of the disruption of reference memory, including general
aspects of executive function, reasoning, and goal-
oriented manipulation of acquired information (Cleary
et al., 2005; Poling et al., 2008).
RRRs are generally measured as a safeguard to ensure
that decreases in response rates AQ6are not misconstrued as
direct central nervous system effects. Consequently, they
are usually measured to provide information on the
general state of health of an experimental animal, and a
fall in RRRs accompanied by a decrease in cognitive
ability would indicate that any conclusion suggesting
central effects might be the result of an experimental
confound. IH injections of aggregated Aβ1–42 and aggre-
gated NAC61–95 resulted in memory deficits (Fig. 3), and
RRRs increased following IH injections of aggregated
Aβ1–42 (Fig. 4) and aggregated NAC61–95 (Fig. 5). These
findings indicate that the IH-aggregated peptide injec-
tion models employed here had detrimental effects on
memory function and associated effects on increased
behavioral output (agitation). These findings are impor-
tant because, although there is one mouse model of AD
in which APP23 mice have been found to show memory
deficits and increased aggressiveness (Vloeberghs et al.,
2006), there is very little in the literature of preclinical
models of dementia that addresses the issue of memory
decline and a correlation with extraneous problematic
behaviors. Yet, problem behaviors, such as agitation, are
highly prevalent in dementia, and specific pharmacolo-
gical interventions that have not been screened against
overall outcomes for the patient are frequently used in
their treatment.
A recent review of investigational compounds for the
treatment of agitation in dementia (Garay et al., 2016)
considered the efficacy of drugs in ongoing or newly
completed clinical trials. This review identified 24 clin-
ical trials: drugs in phase III included an antipsychotic, an
antidepressant, a novel compound (AVP-786), and a
cannabinoid, and in phase II scylloinositol (ELND005)
was likely to progress to phase III. Therefore, some
headway is being made in this area. Consequently, a
preclinical in-vivo screen using established procedures
for modeling dementia would be of considerable value.
Clinically, agitation in dementia is frequently observed
Fig. 5
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and can range from constant vocalization, wandering, and
severe sleep disturbances, but it has not been given the
research emphasis applied to the basic neurophysiologi-
cal etiology of memory dysfunction in dementia.
However, the management of agitation, psychotic, and
other non-memory-related symptoms of dementia is a
major clinical concern. There is a growing recognition
that neuropsychiatric symptoms, such as agitation, might
increase the rate of progression of dementia. And this is
particularly relevant to AD, where it has been found that
neuropsychiatric symptoms, such as psychosis, agitation,
and aggression, were associated with a more rapid pro-
gression to severe dementia and reduced survival times
(Peters et al., 2015).
A range of pharmacological agents have been employed
in attempts to treat behavioral problems related to
dementia; these include anxiolytic drugs, antidepressant
drugs, anticonvulsant drugs, α-adrenergic and β-adrener-
gic drugs, lithium, hormones, and antipsychotic drugs.
However, the emphasis of preclinical laboratory-based
modeling of dementia has tended to concentrate on
memory dysfunction, because pharmacological interven-
tions for memory dysfunction are seen as a major research
target. As a result, extension of the models employed to
investigate memory to other symptoms commonly
reported in the clinical literature have largely been
overlooked. The findings of the current study indicate
that the technique of bilateral IH injection of pre-
aggregated peptides, aggregated Aβ1–42 as a model of AD
and aggregated NAC61–95 as a model of DLB, can be
extended to provide a useful in-vivo animal model of the
syndrome of agitation that is commonly associated with
cognitive decline in dementia. This model could be used
to investigate pharmacological interventions for agitation,
including aggressive behaviors and sleep disturbances
associated with the disease process. Adopting the pre-
clinical approach to modeling agitation described in the
current study would present a method for screening
drugs that have ameliorative effects on emerging pro-
blem behaviors but that do not have detrimental effects
on the memory functions that have already been com-
promised by the accumulation of neurotoxic aggregates
in the brain.
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